Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27821604.
- Also identified by DOI 10.1158/1078-0432.CCR-15-2815.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy. Osimertinib (Tagrisso, formerly AZD9291; AstraZeneca) is indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It received breakthrough therapy designation, priority review status, and accelerated approval from the FDA. Clin Cancer Res; 23(3); 618-22. ©2016 AACR.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Lung Neoplasms
- Molecular Targeted Therapy
- Neoplasm Proteins
- Piperazines
- Protein Kinase Inhibitors